JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
William Garrett Nichols, the Chief Medical (TASE:BLWV) Officer of Candel Therapeutics , Inc. (NASDAQ:CADL), recently made significant transactions involving the company’s common stock. The transactions come as CADL shares have surged nearly 500% over the past year, with analysts setting price targets between $15 and $25. On March 18, Nichols sold 45,316 shares for a total of $396,995, with prices ranging from $8.36 to $9.00 per share.
In addition to the stock sale, Nichols executed options to acquire shares at significantly lower prices. He acquired 4,584 shares at $3.75 per share and 13,905 shares at $1.29 per share, totaling $35,127 for these transactions. Following these activities, Nichols holds 52,493 shares directly in the $390 million market cap company. According to InvestingPro, CADL is currently trading below its Fair Value, with 8 additional exclusive insights available to subscribers.
These transactions were conducted as part of a 10b5-1 trading plan, which Nichols adopted on November 22, 2024. The stock has shown a notable tendency to move in the opposite direction of the broader market, with a beta of -1.28.
In other recent news, Candel Therapeutics has reported significant advancements in its cancer treatment studies, particularly with its lead asset, CAN-2409. The company announced promising Phase 3 results for CAN-2409 in treating prostate cancer, demonstrating a statistically significant improvement in disease-free survival. Additionally, in a Phase 2 trial for pancreatic ductal adenocarcinoma, CAN-2409 showed a notable increase in median overall survival compared to the control group. Candel is preparing for a Biologics License Application for CAN-2409, aiming for submission in 2026.
Furthermore, Candel has entered a strategic partnership with IDEA Pharma to enhance the commercial strategy for CAN-2409. Analyst firms have shown confidence in Candel’s prospects, with H.C. Wainwright maintaining a Buy rating and Citi initiating coverage with a Buy rating and a $25.00 price target. The company’s pipeline also includes CAN-3110, currently in a Phase 1b trial for high-grade glioma. These developments underscore the potential impact of Candel’s therapies in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.